摘要
目的:研究灵仙新苷(clematichinenoside AR)调节血脂及抗动脉粥样硬化的作用。方法:采用高脂饲料喂饲和腹腔注射维生素D3结合腹腔注射LPS建立大鼠动脉粥样硬化模型,造模成功后灌胃给予高、中、低剂量的AR(32,16,8 mg.kg-1.d-1),8周后测定大鼠血清胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、肿瘤坏死因子(TNF-α)、一氧化氮(NO)及诱导型一氧化氮合酶(iNOS);取其胸主动脉进行油红O染色,观察大鼠胸主动脉内膜脂质沉积情况;取肝脏进行常规HE染色,观察肝脏病变。结果:AR高、中剂量组能显著降低高血脂症大鼠血清TC,TG,LDL-C,TNF-α,NO水平和iNOS活力,升高HDL-C水平,差异具有统计学意义(P<0.05)。同时,AR能减少主动脉内皮脂质沉积,改善肝脏的脂肪变性和炎症细胞浸润。结论:AR具有调节血脂,减轻动脉粥样硬化发生和发展的作用,该作用与其调节NO及其合酶的形成和表达相关。
Objective： To examine whether clematichinenoside（AR） affects blood lipid metabolism,atherosclerosis and hepatic lipogenesis in rats.Methods： Firstly,hypercholesterolemia in rats was induced by feeding a high-fat with intraperitoneal injection of vitamin D3 and LPS.Then the rats were intragastrically administered with AR（32,16 and 8 mg·kg-1·d-1）.The levels of TC,TG,LDL-C,HDL-C,TNF-α,NO and iNOS in serum were analyzed.The lipidoses of aorta was detected by oil red O staining in frozen sections.Finally the pathological changes in liver lipogenesis were examined.Results： AR significantly reduced the levels of TC,TG,LDL-C,TNF-α,NO and iNOS,and increased the levels of HDL-C as compared with control hypercholesterolemic rats.The oil red O staining in frozen sections showed that AR decreased the lipidoses of aorta.Pathological examination showed that AR attenuated hepatic cell steatosis and inflammatory cell recruiting.Conclusion： AR can modify lipid metabolism,decrease the lipidoses of aorta and attenuate hepatic lipogenesis in hypercholesterolemic rats.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第1期83-88,共6页
Chinese Journal of New Drugs
基金
天然药物活性组分与药效国家重点实验室资助项目(JKGQ201108)
